Physician profile

Karen E Coblens

Internal Medicine · Danbury, CT

NPI 1063479848

$3,868.17

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $564.70 2019-2022
Astrazeneca Pharmaceuticals Lp $510.53 2019-2022
Novo Nordisk INC $487.02 2019-2020
Pfizer INC. $389.31 2019-2020
Glaxosmithkline, LLC. $218.00 2019
Merck Sharp & Dohme LLC $214.40 2019-2020
Amarin Pharma, INC. $189.60 2019-2020
Novartis Pharmaceuticals Corporation $183.78 2019-2020
Boston Scientific Corporation $147.04 2022
Sanofi-Aventis U.S. LLC $114.01 2019
Astellas Pharma US INC $99.95 2019
Allergan, INC. $99.50 2019-2020
Janssen Pharmaceuticals, INC $94.18 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $89.61 2019-2020
Amgen INC. $87.86 2019-2020
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $84.67 2019-2020
Medtronic Vascular, INC. $61.20 2019
Takeda Pharmaceuticals U.S.A., INC. $59.16 2019
Daiichi Sankyo INC. $47.41 2019
Sanofi Pasteur INC. $44.76 2019-2020
Genentech USA, INC. $34.66 2019-2020
Therapeuticsmd, INC. $30.89 2019
Qiagen, LLC $15.93 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Karen E Coblens

$3,868.17

in general payments reported 2019-2025

Years
2019-2022
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/3239/karen-e-coblens

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.